GB2616129A - Methods and systems for predicting response to anti-TNF therapies - Google Patents
Methods and systems for predicting response to anti-TNF therapies Download PDFInfo
- Publication number
- GB2616129A GB2616129A GB2303624.7A GB202303624A GB2616129A GB 2616129 A GB2616129 A GB 2616129A GB 202303624 A GB202303624 A GB 202303624A GB 2616129 A GB2616129 A GB 2616129A
- Authority
- GB
- United Kingdom
- Prior art keywords
- tnf therapy
- responsive
- subjects
- gene expression
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract 36
- 238000000034 method Methods 0.000 title claims abstract 34
- 230000004044 response Effects 0.000 title claims abstract 14
- 230000014509 gene expression Effects 0.000 claims abstract 27
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 9
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 229960000598 infliximab Drugs 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 229960002964 adalimumab Drugs 0.000 claims 4
- 101000832685 Homo sapiens Small ubiquitin-related modifier 2 Proteins 0.000 claims 3
- 238000003559 RNA-seq method Methods 0.000 claims 3
- 102100024542 Small ubiquitin-related modifier 2 Human genes 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 208000002557 hidradenitis Diseases 0.000 claims 2
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229960004247 tofacitinib citrate Drugs 0.000 claims 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 claims 1
- 229960004914 vedolizumab Drugs 0.000 claims 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Bioethics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073336P | 2020-09-01 | 2020-09-01 | |
| PCT/US2021/048346 WO2022051245A2 (en) | 2020-09-01 | 2021-08-31 | Methods and systems for predicting response to anti-tnf therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202303624D0 GB202303624D0 (en) | 2023-04-26 |
| GB2616129A true GB2616129A (en) | 2023-08-30 |
Family
ID=80492102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2303624.7A Pending GB2616129A (en) | 2020-09-01 | 2021-08-31 | Methods and systems for predicting response to anti-TNF therapies |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230282367A1 (enExample) |
| EP (1) | EP4208256A4 (enExample) |
| JP (1) | JP2023538963A (enExample) |
| KR (1) | KR20240018404A (enExample) |
| CN (1) | CN117615780A (enExample) |
| AU (1) | AU2021336781A1 (enExample) |
| CA (1) | CA3191195A1 (enExample) |
| GB (1) | GB2616129A (enExample) |
| IL (1) | IL300978A (enExample) |
| MX (1) | MX2023002446A (enExample) |
| WO (1) | WO2022051245A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178546A1 (en) | 2018-03-16 | 2019-09-19 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
| JP2022541125A (ja) | 2019-06-27 | 2022-09-22 | サイファー メディシン コーポレーション | 患者を層別化するための分類子の開発 |
| WO2023150731A2 (en) * | 2022-02-04 | 2023-08-10 | Scipher Medicine Corporation | Systems and methods for predicting response to anti-tnf therapies |
| CN120015309B (zh) * | 2025-01-14 | 2025-12-12 | 中国人民解放军军事科学院军事医学研究院 | 用于急性高原反应（ams）易感性分群的装置 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100303813A1 (en) * | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| US20110160085A1 (en) * | 2008-08-25 | 2011-06-30 | Katherine Li | Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders |
| US20120039900A1 (en) * | 2007-05-31 | 2012-02-16 | Abbott Laboratories | Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disorders |
| WO2019018440A1 (en) * | 2017-07-17 | 2019-01-24 | The Broad Institute, Inc. | HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011014349A1 (en) * | 2009-07-28 | 2011-02-03 | Centocor Ortho Biotech Inc. | Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis |
| CA3295783A1 (en) * | 2011-05-10 | 2026-03-02 | Prometheus Laboratories, Inc. | Methods of disease activity profiling for personalized therapy management |
| JP7054990B2 (ja) * | 2014-03-27 | 2022-04-15 | ジェネンテック， インコーポレイテッド | 炎症性腸疾患の診断及び治療のための方法 |
| GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
| WO2019178546A1 (en) * | 2018-03-16 | 2019-09-19 | Scipher Medicine Corporation | Methods and systems for predicting response to anti-tnf therapies |
| EP3881233A4 (en) * | 2018-11-15 | 2022-11-23 | Ampel Biosolutions, LLC | DISEASE PREDICTION AND TREATMENT PRIORIZATION WITH MACHINE LEARNING |
| CA3119294A1 (en) * | 2018-11-15 | 2020-05-22 | Janssen Biotech, Inc. | Methods and compositions for prediction of response to a therapy of inflammatory bowel disease |
| JP2022541125A (ja) * | 2019-06-27 | 2022-09-22 | サイファー メディシン コーポレーション | 患者を層別化するための分類子の開発 |
-
2021
- 2021-08-31 WO PCT/US2021/048346 patent/WO2022051245A2/en not_active Ceased
- 2021-08-31 GB GB2303624.7A patent/GB2616129A/en active Pending
- 2021-08-31 CA CA3191195A patent/CA3191195A1/en active Pending
- 2021-08-31 MX MX2023002446A patent/MX2023002446A/es unknown
- 2021-08-31 EP EP21864967.1A patent/EP4208256A4/en not_active Withdrawn
- 2021-08-31 CN CN202180074291.7A patent/CN117615780A/zh active Pending
- 2021-08-31 JP JP2023513939A patent/JP2023538963A/ja active Pending
- 2021-08-31 AU AU2021336781A patent/AU2021336781A1/en not_active Abandoned
- 2021-08-31 KR KR1020237011014A patent/KR20240018404A/ko active Pending
- 2021-08-31 IL IL300978A patent/IL300978A/en unknown
-
2023
- 2023-02-28 US US18/176,288 patent/US20230282367A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120039900A1 (en) * | 2007-05-31 | 2012-02-16 | Abbott Laboratories | Biomarkers predictive of the responsiveness to tnfalpha inhibitors in autoimmune disorders |
| US20100303813A1 (en) * | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| US20110160085A1 (en) * | 2008-08-25 | 2011-06-30 | Katherine Li | Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders |
| WO2019018440A1 (en) * | 2017-07-17 | 2019-01-24 | The Broad Institute, Inc. | HUMAN COLON CELL ATLAS IN GOOD HEALTH AND WITH HEMORRHAGIC RECTO-COLITIS |
| US20210325387A1 (en) * | 2017-07-17 | 2021-10-21 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
Non-Patent Citations (1)
| Title |
|---|
| GHIASSAIN et al., "Network-based response module comprised of gene expression biomarkers predicts response to infliximab at treatment initiation in ulcerative colitis", Translational Research, (20210506), vol. 1931-524, no. 21, pages 1 - 9, [PX] 1-4, 29, 30, 33-36, 42-44,46 * . entire document * * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230282367A1 (en) | 2023-09-07 |
| CA3191195A1 (en) | 2022-03-10 |
| AU2021336781A9 (en) | 2025-03-13 |
| GB202303624D0 (en) | 2023-04-26 |
| WO2022051245A3 (en) | 2022-04-14 |
| WO2022051245A2 (en) | 2022-03-10 |
| IL300978A (en) | 2023-04-01 |
| MX2023002446A (es) | 2023-05-12 |
| AU2021336781A1 (en) | 2023-05-11 |
| CN117615780A (zh) | 2024-02-27 |
| EP4208256A4 (en) | 2024-09-25 |
| JP2023538963A (ja) | 2023-09-12 |
| EP4208256A2 (en) | 2023-07-12 |
| KR20240018404A (ko) | 2024-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7297015B2 (ja) | エピジェネティックな染色体相互作用 | |
| Lussier et al. | DNA methylation as a predictor of fetal alcohol spectrum disorder | |
| JP2021518432A5 (enExample) | ||
| GB2603294A (en) | Developing classifiers for stratifying patients | |
| JP2017079772A (ja) | 癌の分子的診断検査 | |
| CN108624650B (zh) | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 | |
| JP2023538963A5 (enExample) | ||
| CA2889087C (en) | Diagnostic method for predicting response to tnf.alpha. inhibitor | |
| JP2022541125A5 (enExample) | ||
| JP2015536667A (ja) | 癌のための分子診断検査 | |
| Simon | Genomic clinical trials and predictive medicine | |
| CN116334225A (zh) | 一种以非疾病诊断或治疗为目的的非小细胞肺癌pd-1免疫治疗响应预测方法 | |
| GB2622147A (en) | Methods of classifying and treating patients | |
| CN113755596B (zh) | 一种检测喉鳞癌放疗敏感性相关基因atm和atr基因突变的试剂盒及其应用 | |
| CN107058521A (zh) | 一种检测人体免疫状态的检测系统 | |
| WO2012033999A2 (en) | Biomarkers for predicting kidney and glomerular pathologies | |
| CN112481380A (zh) | 一种评估晚期膀胱癌抗肿瘤免疫治疗反应性和预后生存的标志物及其应用 | |
| US20170145501A1 (en) | Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response | |
| WO2021026129A1 (en) | Compositions and methods for detecting sepsis | |
| US20130218581A1 (en) | Stratifying patient populations through characterization of disease-driving signaling | |
| HK40100171A (en) | Methods and systems for predicting response to anti-tnf therapies | |
| CN108570501B (zh) | 多发性骨髓瘤分子分型及应用 | |
| US20030194701A1 (en) | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis | |
| CN114324887B (zh) | 免疫球蛋白a肾病t细胞诊断标志物 | |
| WO2019087200A1 (en) | Prognostic methods for anti-tnfa treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40100171 Country of ref document: HK |